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OBJECTIVES: Ticagrelor, co-administered with acetylsalicylic acid, is a new anti-
platelet therapy for patients with acute coronary syndrome (ACS) aimed at pre-
venting thrombotic events [i.e., cardiovascular mortality, myocardial infarction
(MI) and stroke]. The goal was to determine the cost per life year gained (LYG) for
ticagrelor compared to current standard therapy (clopidogrel) using a cost-effec-
tiveness analysis framework based on the published results from the Platelet In-
hibition and Patient Outcomes (PLATO). METHODS: A Markov model framework
was developed in order to evaluate the costs and benefits of ticagrelor over a life-
time time horizon. The clinical outcomes consisted of four health states: “MI”,
“Stroke”, “All Cause Mortality” and “Recovered”, with frequencies derived from the
pivotal PLATO study at one year. These health states were extrapolated into the
future via “Live” and “Die” scenarios. Resources and costs (2010 Canadian $) were
obtained from the literature or public domain. A 5% discount rate was applied to all
the cost and clinical inputs after the first year. RESULTS: An incremental cost
effectiveness ratio (ICER) of $1125/LYG was determined. Probabilistic sensitivity
analysis presented greater than 99% of all iterations resulting in an ICER less than
$50,000/LYG. The economic model was most sensitive to the probability of death
within one year of ticagrelor or clopidogrel treatment. CONCLUSIONS: Based on
outcomes in the PLATO trial, the use of ticagrelor instead of clopidogrel for treat-
ment of ACS in Canada is associated with an ICER of $1,125/LYG.
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OBJECTIVES: Diabetic nephropathy significantly increases the risk of cardiovascu-
lar disease (CVD) and end-stage renal disease (ESRD) in hypertensive patients.
According to the AVOID study, the direct renin-inhibitor aliskiren, when added to
losartan and optimal antihypertensive therapy in patients with hypertension, type
2 diabetes (T2DM) and diabetic nephropathy, significantly (p0.001) reduced albu-
minuria by 20% over 6 months, as assessed by urinary albumin-creatinine ratio
(UACR). This simulation examines the potential long-term clinical benefits and
costs of add-on therapy with aliskiren in hypertensive patients with T2DM and
diabetic nephropathy in Germany. METHODS: We developed a micro-simulation
model to depict the progression to ESRD, measured by UACR levels over time.
Patients at model entry were on maximal recommended doses of losartan and
optimal antihypertensive therapy, and either continued this regimen or received
aliskiren as an add-on therapy. In scenario analyses, different assumptions on the
maintenance of the 20% UACR-reduction were made. Expected costs of pharmaco-
therapy and medical care were calculated based on German-specific sources over
10 years applying an annual discount rate of five percent. Sensitivity analyses were
conducted to analyze the impact of different input parameters. RESULTS: Add-on
therapy with aliskiren was projected to reduce the risk of ESRD by 1.8% and delay
the onset of ESRD by 0.15 years assuming that the effects of aliskiren on UACR-
reduction are maintained over 5 years. While discounted costs of pharmacother-
apy were estimated to increase by 1762€ per patient with aliskiren, costs of ESRD-
related care were estimated to decrease by 3804€ over this same period, yielding
total cost savings. Findings were sensitive to the duration over which the benefits
of add-on therapy with aliskiren were assumed to be maintained. CONCLUSIONS:
In hypertensive patients with T2DM and diabetic nephropathy receiving losartan
and optimal antihypertensive therapy, add-on therapy with aliskiren is projected
to yield clinical benefits and cost savings.
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OBJECTIVES: To evaluate the cost-effectiveness of a one-year treatment period
with 90 mg twice daily Ticagrelor compared to 75 mg/day Clopidogrel in acute
coronary syndrome (ACS) patients with or without ST-segment elevation from the
third-party-payer perspective in Greece. METHODS: An existing model consisting
of a one-year decision tree based on the PLATO trial data and a long-term extrap-
olation Markov model was adapted to the Greek health-care setting. Utility values
obtained from the PLATO trial were used to estimate quality-adjusted life years
(QALY) for both the decision tree and the Markov model. Local unit costs in com-
bination with resource use data collected within the PLATO trial were used to
estimate the costs incorporated in the analysis. These costs included treatment
and medication costs, cost for the management of adverse events, hospitalization,
outpatient visits, rehabilitation and nursing costs. Cost-effectiveness and cost-
utility was expressed as the incremental cost per life year gained (LYG) and QALY
gained (ICER), respectively. RESULTS: Implementing a lifetime horizon, the analy-
sis predicts a discounted survival of 11.63 years in the Ticagrelor treatment group
and 11.48 years in the Clopidogrel treatment group. The corresponding discounted
QALYs were 9.78 and 9.65, respectively. The cumulative lifetime costs per patient
were €24,967 and €24,170, for Ticagrelor and Clopidogrel treatment arm, respec-
tively. The ICER was €5239 for each LYG and €6079 for each QALY saved. Imple-
menting a 5-year horizon analysis, results in a discounted survival of 4.36 and 4.31
years for Ticagrelor and Clopidogrel treatment respectively. The QALYs and costs
per patient were 3.77 and €15,239 for Ticagrelor and 3.73 and €14,604 for Clopi-
dogrel. The ICER in this case was €12,631 for each LYG and €14,176 for each QALY
saved. CONCLUSIONS:One-year treatment with Ticagrelor in addition to aspirin is
a cost-effective treatment option vs Clopidogrel plus aspirin in patients with ACS in
Greece.
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OBJECTIVES: Chronic heart failure (HF) is a major cause of morbidity and mortality
and a growing burden to the healthcare system. The objective was to assess the
cost-effectiveness of candesartan cilexetil, an angiotensin II type 1 receptor blocker
(ARB) for the treatment of HF in the Austrian setting. METHODS: A pre-specified
economic evaluation was conducted on resource utilization prospectively col-
lected alongside the CHARM programme. We examined the effect of adding can-
desartan in all 7599 patients randomized. All patients were considered to have
been managed in Austria. Our analysis takes the perspective of a third party payer.
CHARM consisted of a series of parallel randomized clinical trials comparing can-
desartan with placebo (standard therapy) in patients with NYHA Class II-IV HF: -
CHARM-Alternative (LVEF 40% patients not receiving ACE inhibitors because of
previous intolerance); - CHARM-Added (LVEF 40% patients currently receiving
ACE inhibitors); - or CHARM-Preserved (LVEF  40% patients). Primary outcome of
the overall programme: all-cause mortality; for the component trials: composite of
cardiovascular death and hospital admission for HF. Resource use was collected
prospectively on drug treatment, patients admitted to hospital, admissions for
cardiovascular reasons, and procedures/operations. These data were used to de-
termine the additional direct costs incurred, and potential savings made with can-
desartan. Unit costs were elicited from published Austrian sources in accordance
with local guidelines. 2008 was chosen as the price year. RESULTS: Adjunctive
treatment with candesartan in CHARMAlternative and CHARM-Added led to clin-
ical benefits and, depending on the trial, to either cost savings or low additional
costs. CONCLUSIONS: Not only does candesartan improve all important clinical
outcomes in HF but also offers these benefits at little or no additional cost to the
health care system; indeed, its use in patients with HF and reduced LV systolic
function may lead to an actual reduction in the direct costs of healthcare in Austria.
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OBJECTIVES: Increasing real-life adherence to statin therapy is important to
achieve the clinical benefits of reducing cardiovascular events (CVEs) reported in
randomized clinical trials (RCTs). The aim of this pilot study was to determine the
cost-effectiveness of a pharmaceutical care intervention program in community
pharmacies, aimed to increase statin adherence for the secondary prevention of
CVEs. METHODS: Meta-analyses of five RCTs were performed to determine the
clinical efficacy of statins for secondary prevention, adjusted for different levels of
therapy adherence. A Markov model with a lifelong time horizon was developed to
estimate the influence of statin adherence on CVEs: stroke, myocardial infarction
(MI), revascularization and mortality. Baseline adherence was calculated in a large
Dutch prescription database, using the proportion of days covered (PDC) method.
The effect of pharmacists’ interventions on statin adherence was derived from
literature. A Dutch health care provider’s perspective was adopted; costs and ef-
fects were discounted at 4.0% and 1.5% per annum, respectively. RESULTS: Adher-
ence to statin therapy for secondary prevention in The Netherlands was 73.0%. In
a cohort of 1000 patients, a 7% increase in adherence resulted in a reduction of 1.9
non-fatal strokes, 0.5 fatal strokes, 7.9 non-fatal MIs, 3.7 fatal MIs and 9.1 revascu-
larizations. Additional medication and intervention costs in the intervention group
were €56,000; the cost-savings due to reduced CVEs were €109,000. Overall, the
pharmaceutical care program resulted in 53 quality-adjusted life years (QALYs)
gained and cost-savings of €53,000. CONCLUSIONS: Pharmaceutical care programs
in community pharmacies can improve statin adherence for secondary prevention
of CVEs. At a reasonable level of intervention effectiveness, the programs resulted
in both clinical benefits and cost-savings. The model developed in this pilot study
will be used to estimate the cost-effectiveness of a pharmaceutical care program
(the MeMO intervention) in the The Netherlands that is currently under clinical
evaluation.
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OBJECTIVES: The multicentre, double-blind, randomized PLATO trial showed that
treatment with ticagrelor  aspirin reduced the risk of myocardial infarction,
stroke or death from vascular causes without a significant increase in major bleed-
ing compared to clopidogrel  aspirin treatment in patients with ACS. The long-
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term cost-effectiveness is evaluated using a 12-month treatment period with ti-
cagrelor versus clopidogrel in patients with ACS based on PLATO trial data from the
Mexican public and private perspective. METHODS: The cost-effectiveness model
is divided into two parts: a short-term decision tree based on data from the PLATO
trial to estimate rates of cardiovascular events, healthcare costs, and health-re-
lated quality of life for the 12 months of therapy and a long-term Markov model to
estimate quality-adjusted survival and costs conditional on whether a non-fatal
MI, a non-fatal stroke or no MI or stroke occurred during the 12 months of therapy.
Costs were calculated by applying 2010 Mexican unit costs. The daily drug price
used was $2.05 and $4.91 for clopidogrel and ticagrelor, respectively. The estimated
mean costs and QALYs are calculated over a lifetime time horizon and presented as
incremental cost per QALY. Probabilistic sensitivity analyses were performed.
RESULTS: Ticagrelor was associated with a QALY gain of 0.10; this was primarily
driven by lower mortality and fewer non fatal MI’s resulting in an incremental cost
per QALY gained of $7670 and $7073 for the public and private healthcare sector,
respectively. Probabilistic sensitivity analysis indicated that ticagrelor has more
than 99% probability of being more cost-effective than clopidogrel at a willingness
to pay of $30,000 per QALY. The results were consistent in all ACS subgroups.
CONCLUSIONS: Ticagrelor  aspirin is a cost effective treatment compared to
clopidogrel  aspirin for one year treatment in ACS patients based on the PLATO
trial and Mexican unit costs.
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Recently, ticagrelor showed a statistically significant absolute reduction (1.1%/
year) in cardiovascular (CV) mortality and in myocardial infarction (MI) (1.1%/year)
compared to clopidogrel in acute coronary syndrome (ACS) patients (from pub-
lished results of the PLATO trial). The majority of earlier ACS trials (including CURE
- placebo vs. clopidogrel and TRITON - clopidogrel vs. prasugrel) have not shown
this significant reduction in CV mortality. OBJECTIVES: To estimate the cost-effec-
tiveness of 1-year add-on therapy to aspirin with ticagrelor versus clopidogrel in
patients with ACS in the Dutch setting, based on the published results from PLATO.
METHODS: A published Markov cost-effectiveness model with MI, stroke, death
and subsequent events as health states is used to assess the cost-effectiveness of
ticagrelor in comparison to clopidogrel. In the model relevant utilities and costs are
linked to the health states. Short-term probabilities are based on the published
PLATO trial, while probabilities for subsequent events are assumed to change with
time and occurring events. Several sources were used for these extrapolations. The
cost-effectiveness was tested over daily acquisition cost of ticagrelor varying be-
tween €1 and €7 higher than clopidogrel. Relevant discount rates were applied and
probabilistic sensitivity analyses were conducted. RESULTS: Considering direct
medical costs only, the incremental cost-effectiveness ratios (ICERS) when the cost
of ticagrelor is assumed to be €1, €3, €5, and €7 higher than clopidogrel per day are
estimated at €3,742/QALY, €12,058/QALY, €20,374/QALY, and €28,691/QALY respec-
tively. Probabilistic sensitivity analyses show that ticagrelor is expected to be cost-
effective at a willingness to pay of €30,000 in 100.0%, 98.2%, 89.4%, and 58.0% of
cases when the price is assumed to be €1, €3, €5, or €7 higher than clopidogrel per
day, respectively. CONCLUSIONS: The reduction in mortality seen in the PLATO
trial translates to favorable cost-effectiveness results for ticagrelor, assuming the
price difference over clopidogrel does not exceed €7.50 per day.
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OBJECTIVES: The PLATO trial was a multicentre, double-blind, randomized trial
comparing clopidogrel  aspirin and ticagrelor  aspirin for treatment of patients
with ST-elevation and non-ST-elevation acute coronary syndromes (ACS). The re-
sults showed a significant reduction for ticagrelor in the primary composite end-
point – cardiovascular deaths, myocardial infarction, or stroke - without a signifi-
cant increase in major bleeding. Based on PLATO trial data long-term cost-
effectiveness was evaluated for 12-month treatment with ticagrelor versus
clopidogrel in patients with ACS, from the Brazilian public health care perspective.
METHODS: For the analysis of cost-effectiveness a two-part cost-effectiveness
model was used. The first part was a 12-month decision tree using PLATO trial data
to estimate rates of cardiovascular events, healthcare costs, and health-related
quality of life for the 12 months of therapy. The second part was a long-term
Markov model estimating quality-adjusted survival and costs conditional on
whether a non-fatal MI, a non-fatal stroke, or no MI or stroke occurred during the 12
months treatment. The model applied a lifetime horizon to calculate mean costs
and QALYs. The results are presented as incremental cost-effectiveness ratios (IC-
ER’s). Daily costs of $1.62 for generic clopidogrel and $4.58 for ticagrelor were ap-
plied. Other costs were calculated by applying Brazilian year 2010 unit costs. Prob-
abilistic sensitivity analysis was performed. RESULTS: Ticagrelor was associated
with a QALY gain of 0.10, primarily driven by lower cardiovascular mortality. The
resulting incremental cost per QALY gained was $8966 in the public sector. Proba-
bilistic sensitivity analysis indicated that ticagrelor had more than 99% probability
of being cost-effective at a willingness to pay of $30,000 per QALY. The results were
consistent in all analyzed subgroups. CONCLUSIONS: Based on the PLATO trial
data one year treatment with ticagrelor  aspirin versus clopidogrel  aspirin in
ACS patients is cost-effective from a Brazilian public health care perspective.
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OBJECTIVES: To evaluate the long term cost-effectiveness of rosuvastatin versus
generic atorvastatin in the treatment of patients at high cardiovascular risk (CVR)
5% SCORE or patients with established cardiovascular disease in Spain.METHODS:
The efficacy data from STELLAR trial (Statin Therapies for Elevated Lipid Levels
compared Across doses to Rosuvastatin) was used to simulate cLDL goal attain-
ment at different doses of rosuvastatin and generic atorvastatin during an initial
period of one year. These results were combined in the long term through a Markov
model which estimated the number of cardiovascular events and their impact on
quality of life in patients at high CVR using the Framingham risk equations. The
model estimated quality adjusted life years (QALY) and costs (drug and events
costs) up to 20 years. The analysis was conducted from the Spanish National Health
System perspective. 3% annual discount rate was applied to costs (€ 2010) and
outcomes. Cost-effectiveness was estimated in several subgroups of patients at
high CVR according to blood pressure, smoking status, age, cholesterol levels and
established cardiovascular disease. RESULTS: In primary prevention of cardiovas-
cular events in patients at high risk, rosuvastatin was a cost-effective option (cost/
QALY less than €30,000) versus generic atorvastatin in most of the subgroups ana-
lyzed. In patients with established cardiovascular disease, rosuvastatin was a cost-
effective option in all males subgroups (ICERs between €4,000 and €18,000 per
QALY) and in most of the females subgroups. CONCLUSIONS: The treatment of
patients at high cardiovascular risk with rosuvastatin was more effective than
generic atorvastatin in terms of survival and quality adjusted survival. Incremental
cost-effectiveness ratios were below the commonly accepted efficiency threshold
in Spain (€30,000) in most of the defined subpopulations by different combination
of risk factors.
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OBJECTIVES: 1) To estimate the time and cost of discharge for patients receiving
the current antithrombotic standard of care, warfarin / a heparin product at a
large US academic medical center, and 2) to estimate the system-level impact of a
hypothetical new oral antithrombotic in terms of improved discharge efficiency.
METHODS: Data were obtained from 2010 institutional metrics: patient volume,
major diagnoses (e.g., orthopedic surgery, atrial fibrillation), and resource require-
ments (time and cost of personnel providing antithrombotic discharge counseling;
time and cost of INR-related discharge delays). Metrics were coded as inputs in a
MS Excel model to estimate the potential time and cost impact of changes in pa-
tient volume, personnel providing counseling, or addition of novel oral agents to
the formulary. It was assumed that 80% of warfarin patients would receive the
novel antithrombotic, that these drugs would reduce discharge counseling time by
70%, and would not require INR testing. The cost per day of the new agent was
assumed to be $7 versus $0.82 for warfarin, and the bed of discharged patients was
assumed to be refilled with a new patient 100% of the time at a reimbursement rate
of $1500/day. RESULTS: Based on 1000 patients with a LOS of 4 days, efficiency
impacts of the new agent were estimated as follows: 4000 hours through avoidance
of INR-related delays, 400 hours through elimination of delayed discharge coun-
seling, 284 hours in reduced time to administer discharge counseling. Total patient
days saved by the new drug were 142 per year, translating to $213,000 in revenue
opportunity by improving the efficiency of the discharge process. Additional drug
costs to the facility were estimated to be $19,776 assuming drug prices and patient
volume are consistent with model inputs. CONCLUSIONS: The model quantifies
the system-level impact of new oral antithrombotics and informs formulary deci-
sion making.
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OBJECTIVES: To compare the efficiency of three strategies for the stenosis of the
femoropopliteal sector treatment: bypass surgery (BP), percutaneous transluminal
angioplasty with selective stent insertion (PTA/S), and percutaneous transluminal
angioplasty with selective stent insertion followed by possible bypass surgical re-
intervention (PTA/S/BP). METHODS: An economic evaluation was developed by
implementing a Markov model with three main branches representing each of the
strategies studied. We used a time horizon of 30 years, discounting 3% to costs and
effects. The measure of effectiveness was years of quality-adjusted life (QALYs).
Probabilistic and multivariate sensitivity analysis was performed by using Monte
Carlo (MC) methods. Acceptability curves and the expected value of perfect infor-
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